WeVote
Log In

Bill

Bill

A 9248

Requires pharmaceutical drug manufacturers and wholesalers to annually disclose all gifts to certain health care practitioners

2025 Regular Session Introduced by Dave DiPietro

Requires annual disclosure of all gifts from drug manufacturers and wholesalers to designated health care practitioners to boost transparency for industry and the public.

REFERRED TO HEALTH
0
WeVote Research Nonpartisan
Bill Summary · A 9248

Summary of Bill A 9248

Purpose and intent

  • Aims to increase transparency in the relationship between pharmaceutical drug manufacturers, wholesalers, and health care practitioners by requiring annual disclosure of gifts.
  • The bill targets disclosures related to gifts provided to “certain health care practitioners,” seeking to inform the public and stakeholders about industry interactions with clinicians.

Key provisions (high-level)

  • Annual disclosure requirement: Pharmaceutical drug manufacturers and wholesalers would be required to disclose all gifts given to designated health care practitioners on an annual basis.
  • Scope of gifts and recipients: The bill refers to “all gifts” and to “certain health care practitioners.” The specific definitions of which entities qualify as recipients and what constitutes a gift are defined within the bill text (not provided here).
  • Disclosure mechanism: The bill would establish a process or system for reporting these gifts (how disclosures are filed, where they are disclosed, and who has access to the information would be defined in the bill).
  • Enforcement and penalties: Not specified in the provided information. (If included, such details would be in the bill text.)
  • Effective date: Not specified in the provided information. (Typically defined in the bill text.)

Affected parties

  • Primary: Pharmaceutical drug manufacturers and pharmaceutical wholesalers.
  • Recipients: Certain health care practitioners who would be the subjects of the gifts disclosure (as defined by the bill).
  • Other potential audiences: The public and state/agency regulators responsible for overseeing compliance and disclosures (exact roles would be defined in the bill).

Procedural and timeline aspects

  • Introduction: November 7, 2025.
  • Status: Referred to the Health committee on November 7, 2025. The legislative actions listing shows the bill being referred to Health on that date (duplicated entry in the provided record).
  • Next steps: Awaiting consideration, potential committee hearings, amendments, and eventual floor votes. No further actions or deadlines are provided in the available information.

Sponsor

  • Primary sponsor: David DiPietro.

Notes and considerations

  • The provided information does not include definitions of “certain health care practitioners,” the precise scope of gifts, the disclosure mechanism, reporting timelines beyond “annually,” penalties, or an effective date. Readers should consult the full bill text and committee materials for exact language, definitions, and procedural timelines.
  • The bill, if enacted, could increase transparency around industry-practitioner interactions and may impact compliance costs for manufacturers and wholesalers.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.